Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03804892
Other study ID # 249734
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date October 1, 2019
Est. completion date December 2024

Study information

Verified date December 2023
Source Liverpool John Moores University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Briefly, participants will be assessed for their eligibility for the study using an oral glucose tolerance test, which involves drinking a sugary drink followed by a series of small blood samples. If eligible, participants will be asked to take part in a fitness test and then two trials which will involve walking on a treadmill at a steady pace. Before and after the exercise a small piece of muscle will be taken from their thigh under local anaesthesia, as well as several small blood samples. Muscle muscle samples will be assessed for lipid metabolites.


Description:

The accumulation of fat in skeletal muscle is linked with insulin resistance in obesity and T2D. However, fat also accumulates in the muscle of lean, healthy people, but they remain insulin sensitive. This is because healthy people are able to burn this fat to generate energy during exercise. However, overweight/obese inactive people can't use muscle fat during exercise in the same manner, which is related to the high blood lipid concentrations that are observed in these individuals. Acipimox is a lipid-lowering agent that specifically reduces the breakdown of fat in adipose tissue and has been shown improve the blood lipid profile of obese individuals and T2D patients, at least in the short-term (1-2 weeks). Previous research has shown that the combination of Acipimox with exercise restores the ability of obese people to burn fat during moderate-intensity cycling exercise. It is now important to test whether Acipimox also increases the ability to burn muscle fat during low-intensity walking in people with prediabetes. If it does, then the next step will be to test whether the combination of Acipimox and walking can lead to improved insulin sensitivity and reduced T2D risk over a longer intervention programme. Twelve people with pre-diabetes will be recruited to undertake two experimental trials in a randomised order. Each trial will involve walking for 45 minutes on a treadmill, with muscle biopsies obtained from the thigh before (basal), immediately following (post-exercise) and 3 h post-exercise. Each trial will be identical, except that participants will ingest either Acipimox or a placebo in a double-blind design. Muscle biopsies will be used to examine differences in muscle fat between the two trials.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 12
Est. completion date December 2024
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender All
Age group 25 Years to 55 Years
Eligibility Inclusion Criteria: - Aged 25-55 years - Overweight or obese (BMI >28 kg.m-2) - Have prediabetes - Not currently using any anti-diabetes medication - Physically inactive (performing less than two 30 min structured exercise sessions per week for the last year) - Not pregnant (or intending to get pregnant during the study) or currently breast feeding - Pre-menopausal - Not currently involved in a weight loss programme or using weight loss medication Exclusion Criteria: - Involved in regular exercise (engaged in more than 2 sessions of structured exercise of >30 min per week) - Currently using anti-diabetes medication (e.g. insulin, metformin) - Currently using niacin/vitamin B3 supplements - Pregnant or breast feeding - Currently engaged in active weight loss programmes or using weight loss medication - Diagnosed with chronic kidney disease

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Body Composition
Participants undergo a 5 minute body scan to determine their body composition.
Maximal aerobic fitness test
Participants will complete a walking fitness text until exhaustion to determine maximal aerobic capacity.
Oral glucose tolerance test
Participants will undergo an OGTT to determine insulin sensitivity.
Other:
Muscle biopsy
Participants will give a small muscle sample pre-, immediately post and 3 hours post- the exercise trial to be assessed for lipid metabolites.
Blood samples
Participants will give 16 blood samples, to be assessed for fatty acids in the blood.

Locations

Country Name City State
United Kingdom Liverpool John Moores University Liverpool Merseyside

Sponsors (4)

Lead Sponsor Collaborator
Liverpool John Moores University Diabetes UK, Liverpool University Hospitals NHS Foundation Trust, Royal Liverpool University Hospital

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Plasma fatty acids levels Blood samples will be assessed for the amount of fatty acids in the blood. A change in the amount of fatty acids in the blood from baseline, to every 15 minute interval from the ingestion of acipimox up until 2 hours 45 minutes. From this point, samples will be every 30 minutes until 3 hours 45 minutes terminates the trial.
Primary Skeletal muscle Diacylglycerol (DAG) levels Muscle biopsies will be assessed for lipid metabolites using liquid chromatography-mass spectrometry. A change from baseline DAGs to DAGS immediately post and 3 hours post exercise trial.
Primary Plasma Glycerol levels Blood samples will be assessed for the amount of glycerol in the blood throughout the exercise trial. A change in the amount of fatty acids in the blood from baseline, to every 15 minute interval from the ingestion of acipimox up until 2 hours 45 minutes. From this point, samples will be every 30 minutes until 3 hours 45 minutes terminates the trial.
Primary IMTG utilisation during exercise Muscle samples will be analysed using confocal immunofluorescence microscopy for the amount of IMTG within the samples. A change in amount of IMTG within the muscle from baseline, to immediately post and 3 hours post the exercise intervention.
See also
  Status Clinical Trial Phase
Recruiting NCT05052918 - The Effect of Exercise and Metformin on Carotid Intima-media Thickness in Patients With Prediabetes N/A
Completed NCT03714646 - Beta Glucan and Acetate Production N/A
Completed NCT03377244 - Healthy Body Healthy Souls in the Marshallese Population N/A
Completed NCT04427982 - Dance and Diabetes/Prediabetes Self-Management N/A
Recruiting NCT05008276 - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed NCT03480022 - Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS Phase 3
Active, not recruiting NCT05290233 - Time Restricted Eating Plus Exercise for Weight Management N/A
Withdrawn NCT05726409 - Mobile Application to Create Healthy Food Preparation Habits for Patients With Diabetes and Prediabetes N/A
Completed NCT02834078 - Effect of BGG on Glucose Metabolism and Other Markers of Metabolic Syndrome N/A
Completed NCT04902326 - Behavioral Economics and Self-Determination Theory to Change Diabetes Risk (BEST Change) N/A
Recruiting NCT04168372 - Fructose: Substrate, Stimulus, or Both? N/A
Completed NCT03272074 - Egg Consumption and Glycemic Control in Individuals With Pre- and Type II-diabetes N/A
Not yet recruiting NCT05939349 - A Prescription for Health Equity: A Healthcare Provider-based Produce Prescription Program for People With Prediabetes and Type 2 Diabetes N/A
Completed NCT04978376 - TRE With Physical Activity for Weight Management N/A
Recruiting NCT03997656 - A Digital Therapy for Diabetes Prevention Among Overweight Adults in Terengganu, Malaysia N/A
Recruiting NCT05166785 - BRInging the Diabetes Prevention Program to GEriatric Populations N/A
Completed NCT01729078 - Dietary Interventions in Prediabetes N/A
Completed NCT04507685 - Asian Indian Prediabetes Study N/A
Completed NCT03292315 - Once Weekly GLP-1 in Persons With Spinal Cord Injury Phase 4
Active, not recruiting NCT05353790 - Dietary Exchanges With Avocado and Mango in Pre-diabetes N/A